Lambert Eaton Myasthenic Syndrome Clinical Trial
Official title:
Treatment of Lambert-Eaton Syndrome With 3, 4-Diaminopyridine
A new drug called 3,4-Diaminopyridine (3,4-DAP) is currently under investigation for
treatment of the symptoms of Lambert-Eaton Myasthenic Syndrome (LEMS). This is an expanded
access trial, which means that although data from this study will be collected and reported
to the US Food and Drug Administration (FDA)and the drug manufacturer, this is not a formal
study of drug in LEMS.
If you decide volunteer, you will be evaluated by a neurologist to determine your eligibility
to receive 3, 4-DAP by a review of your medical history, medication regimen (the medications
you are taking) and a neurological examination. If you are a female of child-bearing
potential, a serum pregnancy test will be done to ensure that you are not pregnant. Once it
is determined that this treatment is appropriate for your care, you will begin taking 3, 4
DAP by mouth in slowly increasing doses. Treatment will begin with 5mg three times a day, as
clinically needed, and if tolerated. You will be monitored for strength and side effects by
routine clinic visits at initial intervals of once a month, increasing to intervals of every
12 months as permitted. Blood will be drawn (approximately 1 tablespoon) at every clinic
visit or as often as the investigator deems necessary to assess your liver/kidney function
and blood counts. You will have an EKG (a test to see how your heart is functioning) at your
first study visit, after 6 months of taking 3,4 DAP and again every 2 years. Treatment will
be continued indefinitely if a good clinical response is achieved. This study is planned to
last indefinitely.
The dosage of 3, 4DAP is individually adjusted. The usual range is 10-15 mg 3-4 times per day
for the full effect and will increase by 50% every two weeks to 10-15 mg three to six times a
day, as needed and if tolerated. Dosages above the full effect level will not provide an
additional benefit and should not be used. 3, 4 DAP is a convulsant (causes seizures). A
total of 100 mg/day is the maximum dosage allowed.
Patients with clinically-confirmed LEMS will receive 3, 4-DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg, three times a day and will increase by 50% every two weeks to 10-15 mg, three to six times a day, as clinically needed, and if tolerated. Patients will be monitored for strength and side effects via routine out-patient clinic visits at initial intervals of 1 month, increasing to intervals of 12 months as permitted. Results of treatment and adverse events will be reported to the FDA. Treatment will be continued indefinitely if a good clinical response is achieved and side effects are tolerable. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01377922 -
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
|
Phase 3 | |
| Active, not recruiting |
NCT00716066 -
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
|
Phase 2 | |
| Approved for marketing |
NCT01825395 -
Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
|